SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%)...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 384; číslo 3; s. 229 - 237
Hlavní autori:	Chen, Peter, Nirula, Ajay, Heller, Barry, Gottlieb, Robert L, Boscia, Joseph, Morris, Jason, Huhn, Gregory, Cardona, Jose, Mocherla, Bharat, Stosor, Valentina, Shawa, Imad, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Shen, Lei, Durante, Michael, Oakley, Gerard, Schade, Andrew E, Sabo, Janelle, Patel, Dipak R, Klekotka, Paul, Skovronsky, Daniel M
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 21.01.2021
Predmet:	Adolescent Adult Aged Aged, 80 and over Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Neutralizing - administration & dosage Antibodies, Neutralizing - adverse effects Asymptomatic Clinical outcomes Coronaviridae Coronaviruses COVID-19 COVID-19 - drug therapy COVID-19 - virology Disease Dose-Response Relationship, Drug Double-Blind Method Emergency medical care Female Hospitalization - statistics & numerical data Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects International organizations Intravenous administration Male Medical research Middle Aged Monoclonal antibodies Original Outpatients Pandemics Patients Placebos Reverse Transcriptase Polymerase Chain Reaction Ribonucleic acid Risk factors RNA RNA, Viral - blood SARS-CoV-2 - genetics SARS-CoV-2 - isolation & purification Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Statistical analysis Viral Load - drug effects Young Adult
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%).
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 A list of the BLAZE-1 investigators is provided in the Supplementary Appendix, available at NEJM.org. Drs. Chen and Nirula contributed equally to this article.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2029849